Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/11016
Title: Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia.
Authors: Crowe, Amy
McMahon, Nicole
Currie, Bart J
Baird, Robert W
Affiliation: Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia..
Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia..
Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT 0810, Australia..
Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia. Electronic address: rob.baird@nt.gov.au..
Issue Date: Aug-2014
Citation: International journal of antimicrobial agents 2014-08; 44(2): 160-2
Abstract: Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/11016
DOI: 10.1016/j.ijantimicag.2014.04.012
Type: Journal Article
Research Support, Non-U.S. Gov't
Subjects: Antimicrobial susceptibility
Burkholderia pseudomallei
Melioidosis
Anti-Bacterial Agents
Burkholderia pseudomallei
Ceftazidime
Drug Resistance, Bacterial
Humans
Melioidosis
Microbial Sensitivity Tests
Northern Territory
Root Cause Analysis
Thienamycins
Trimethoprim, Sulfamethoxazole Drug Combination
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.